CTKB
Cytek Biosciences Inc
NASDAQ · Life Sciences Tools & Services
$4.47
-0.03 (-0.67%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 196.23M | 168.98M | 293.87M | 285.65M | 250.25M |
| Net Income | -5,894,568 | -4,568,252 | 32.42M | 33.87M | 27.85M |
| EPS | — | — | — | — | — |
| Profit Margin | -3.0% | -2.9% | 11.0% | 11.9% | 11.1% |
| Rev Growth | +16.1% | +16.1% | +3.2% | +23.4% | +11.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 4.06M | 4.06M | 209.61M | 185.65M | 183.29M |
| Total Equity | 281.72M | 281.72M | 298.65M | 348.72M | 320.85M |
| D/E Ratio | 0.01 | 0.01 | 0.70 | 0.53 | 0.57 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 30.50M | 24.95M | 48.22M | 45.08M | 40.37M |
| Free Cash Flow | — | — | 19.89M | 30.74M | 26.84M |